-
Important news
-
News
-
In-Depth
-
Shenzhen
-
China
-
World
-
Business
-
Speak Shenzhen
-
Culture
-
Leisure
-
Photos
-
Lifestyle
-
Travel
-
Tech
-
Special Report
-
Digital Paper
-
Opinion
-
Features
-
Kaleidoscope
-
Health
-
Markets
-
Sports
-
Entertainment
-
Business/Markets
-
World Economy
-
Weekend
-
Newsmaker
-
Advertisement
-
Diversions
-
Movies
-
Hotels and Food
-
Yes Teens!
-
News Picks
-
Glamour
-
Campus
-
Budding Writers
-
Fun
-
Qianhai
-
CHTF Special
-
Futian Today
在线翻译:
szdaily -> Speak Shenzhen -> 
Scientists rewrite DNA inside a living patient for the first time
    2026-11-16  08:53    Shenzhen Daily

Scientists have achieved a major milestone in gene editing by using prime editing to correct DNA inside a living patient for the first time, opening a potential new path for treating inherited diseases without removing cells from the body.

Prime Medicine, a U.S.-based biotechnology company, has administered its experimental prime-editing treatment, PM577, to the first participant in a clinical trial targeting Wilson disease, according to a report published on Oct. 23, 2026.

The treatment aims to correct a genetic mutation responsible for Wilson disease - an inherited disorder in which mutations in the ATP7B gene prevent the liver from clearing excess copper, with consequent damage to liver and nerves.

The gene helps produce a protein that removes excess copper from the liver. When it does not function properly, copper can accumulate in the body and damage organs.

Nature reported the dosing as the first known instance of this high-precision technique altering DNA inside a person; initial safety and efficacy data are not expected until 2027.

Currently, patients take drugs that bind to copper to help excrete it from the body or use zinc preparations to block copper absorption in the intestine. Most must take medication for life, and a liver transplant may be needed if severe liver failure occurs.

The experimental therapy uses lipid nanoparticles to deliver gene-editing tools directly into liver cells.

The approach is designed to repair faulty DNA inside the body, potentially reducing the need for more complex procedures that involve modifying cells in a laboratory before returning them to the patient.

Traditional cell-based gene therapies can require intensive chemotherapy to prepare the body to accept modified cells.

Prime editing offers a different approach by aiming to make precise genetic changes directly within the patient’s tissues.

However, the technique also presents challenges. Researchers cannot fully inspect and verify every genetic change before edited cells continue to function and multiply inside the body. This makes accuracy and safety critical areas for further investigation.

Prime Medicine is expected to release initial clinical trial findings in 2027. The results could help researchers assess the treatment’s safety and effectiveness and guide the development of other gene-editing therapies administered directly inside the body.

Although the milestone marks an important step for genetic medicine, further clinical evidence will be needed to determine whether the treatment can safely and effectively help people with Wilson disease.

Prime editing is a gene-editing technology that the Broad Institute, jointly founded in 2019 by Harvard University and the Massachusetts Institute of Technology (MIT), released in the international journal Nature. It is considered an advancement over the CRISPR-Cas9 gene scissors that won the Nobel Prize in chemistry in 2020.

科学家在基因编辑领域实现重大里程碑:首次利用“先导编辑”(prime editing)技术在活体患者体内修正DNA,为无需取出细胞即可治疗遗传性疾病开辟了潜在新路径。

据2026年10月23日发布的一篇报道,美国生物技术公司Prime Medicine已将其实验性先导编辑疗法PM577用于一项针对威尔逊病的临床试验的首名受试者。

该疗法旨在修正导致威尔逊病的基因突变。威尔逊病是一种遗传性疾病,ATP7B基因突变会导致肝脏无法清除过量铜,进而损伤肝脏和神经。该基因有助于产生一种从肝脏清除多余铜的蛋白质。当其功能异常时,铜会在体内蓄积并损害器官。

《自然》杂志报道称,此次给药是已知首例利用这种高精度技术在人体内改变DNA的案例;初步安全性和有效性数据预计要到2027年才会公布。

目前,患者需服用结合铜的药物以帮助其排出体外,或使用锌制剂阻断肠道对铜的吸收。大多数人必须终身服药,若出现严重肝衰竭,可能需要进行肝移植。

该实验性疗法利用脂质纳米颗粒将基因编辑工具直接递送至肝细胞。该方法旨在修复体内的缺陷DNA,有望减少对更复杂流程的需求——这类流程需在实验室中改造细胞后再回输患者体内。传统的细胞基因疗法可能需要强化化疗,以使身体能够接受改造后的细胞。先导编辑则提供了一种不同思路,力求直接在患者组织内实现精准的基因改变。

然而,该技术也面临挑战。研究人员无法在编辑后的细胞于体内继续发挥功能并增殖之前,全面检查和验证每一处基因改变。这使得准确性和安全性成为需进一步研究的关键领域。

Prime Medicine预计将于2027年公布初步临床试验结果。这些结果有助于研究人员评估该疗法的安全性和有效性,并指导其他直接在体内给药的基因编辑疗法的开发。

尽管这一里程碑标志着基因医学迈出重要一步,但仍需进一步的临床证据来确定该疗法能否安全有效地帮助威尔逊病患者。

先导编辑是一种基因编辑技术,由哈佛大学与麻省理工学院(MIT)于2019年联合创立的布罗德研究所发布在国际期刊《自然》上。它被认为是2020年获得诺贝尔化学奖的CRISPR-Cas9“基因剪刀”的进阶技术。

(Translated by DeepSeek)

深圳报业集团版权所有, 未经授权禁止复制; Copyright 2010-2020, All Rights Reserved.
Shenzhen Daily E-mail:szdaily@126.com